Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26660791 | 0.83 | TBXAS1 (0.51) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4342783 | 0.82 | TBXAS1 (0.54) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7771361 | 0.81 | TBXAS1 (0.43) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL14464725 | 0.80 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL14415940 | 0.80 | TBXAS1 (0.53) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL21392728 | 0.79 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22023938 | 0.78 | TBXAS1 (0.59) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11266178 | 0.78 | TBXAS1 (0.77) | TBXAS1 | |
| SCHEMBL2229395 | 0.77 | TBXAS1 (0.62) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4338960 | 0.77 | TBXAS1 (0.49) | TBXAS1CYP17A1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | TBXAS1 96/4885CYP17A1 804/4885CYP19A1 1302/4885 |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | TBXAS1 1517/4885CYP17A1 1497/4885CYP19A1 1629/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | TBXAS1 96/4885CYP17A1 804/4885CYP19A1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.